Shortage of a Protein Linked to Autism in Mice

Mice born with lower amounts of nSR100 protein display the symptoms of autism spectrum disorder, suggesting a functional link.

By | December 20, 2016

WIKIMEDIA, AARON LOGANMice born with normal levels of nSR100 protein appear just fine, and those born with none of the protein tend to die. But according to a December 15 study in Molecular Cell, mice born with a shortage of nSR100 display many of the symptoms of autism spectrum disorder. The study suggests that nSR100 shortage may account for as many as 33 percent of autism cases in mice. “We’ve really hit upon a common mechanism that may account for at least one third of autism spectrum disorder cases,” coauthor Benjamin Blencowe of the University of Toronto told The Globe and Mail.

Blencowe and colleagues first came across nSR100 in 2014, when they discovered that the protein was a key regulator of alternative splicing, a system that cells—especially those in the brain—use to tweak how DNA produces proteins. Subsequent studies revealed that nSR100 levels tend to be lower in the postmortem brain tissue of people with autism. For the present study, Blencowe and colleagues have demonstrated, for the first time, that mice born with low levels of nSR100 in their brain cells indeed display many of the symptoms of autism, including hypersensitivity to environment and impaired sociability.

By studying individual mouse brain cells, the team also determined that any mutation that increases neuronal excitability often leads to lower levels of nSR100 in the cell, a finding that may indicate future targets for autism treatments.

“These are intriguing findings,” Lilia Iakoucheva of University of California, San Diego, who was not involved in the work, told The Globe and Mail.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham